

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins		
Term:	L32 and plural\$ <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		
Display:	20	Documents in <u>Display Format</u> : <input type="checkbox"/>	Starting with Number <input type="text" value="1"/>
Generate:	<input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image		

Search History

DATE: Wednesday, September 08, 2004 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
<u>side by side</u>			<u>result set</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>		
<u>L33</u>	L32 and plural\$	10	<u>L33</u>
<u>L32</u>	L31 near philip	36	<u>L32</u>
<u>L31</u>	braithwaite.in.	505	<u>L31</u>
<u>L30</u>	l20 and inhaler	40	<u>L30</u>
<u>L29</u>	l20 same inhaler	0	<u>L29</u>
<u>L28</u>	L27 and (combination near therap\$)	14	<u>L28</u>
<u>L27</u>	multi near dose near inhaler	112	<u>L27</u>
<u>L26</u>	multi near does near inhaler	0	<u>L26</u>
<u>L25</u>	l24 and inhaler	2	<u>L25</u>
<u>L24</u>	sanders.in. near mark	67	<u>L24</u>
<u>L23</u>	L20 and (dry near powder)	45	<u>L23</u>
<u>L22</u>	L20 same advant\$	8	<u>L22</u>
<u>L21</u>	L20 same stabil\$	1	<u>L21</u>
<u>L20</u>	(combination near therap\$) same (separate near composition)	441	<u>L20</u>
<u>L19</u>	L18 and separate	28	<u>L19</u>
<u>L18</u>	l6 and (combination near therap\$)	31	<u>L18</u>

<u>L17</u>	L16 and powder	137	<u>L17</u>
<u>L16</u>	l12 and asthma	156	<u>L16</u>
<u>L15</u>	L13 and (fluticasone or formoterol)	8	<u>L15</u>
<u>L14</u>	L13 and 15	7	<u>L14</u>
<u>L13</u>	L12 and (dry adj powder)	78	<u>L13</u>
<u>L12</u>	(combination near therap\$) and (separate near composition)	786	<u>L12</u>
<u>L11</u>	l8 and (separate near composition)	8	<u>L11</u>


DB=USPT; PLUR=YES; OP=OR

<u>L10</u>	US-6369115-B1.did.	1	<u>L10</u>
<u>L9</u>	US-6369115-B1.did.	1	<u>L9</u>

DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR

<u>L8</u>	L6 and (respiratory or asthma)	180	<u>L8</u>
<u>L7</u>	L6 abd (respiratory or asthma)	102656	<u>L7</u>
<u>L6</u>	L5 and (dry adj powder)	187	<u>L6</u>
<u>L5</u>	fluticasone same formoterol	381	<u>L5</u>
<u>L4</u>	clarke.in. near jeremy	8	<u>L4</u>
<u>L3</u>	6253762.pn. and (dry near powder)	1	<u>L3</u>
<u>L2</u>	6253762.pn. and powder	1	<u>L2</u>
<u>L1</u>	5709884.pn.	2	<u>L1</u>

END OF SEARCH HISTORY



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Bo	
Search	PubMed	for separate + inhaler				Go	Clear			
		Limits	Preview/Index	History	Clipboard	Details				

About Entrez

Display **Summary** Show: 20 Sort Send to Text

Text Version

Items 121-140 of 207 Previous Page 7 of 11 Next

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

121: [Rolla G, Bucca C, Brussino L.](#) Related Articles, Links

Effect of inhaled norepinephrine on the nitroglycerin-induced bronchodilatation in asthmatics.
Chest. 1995 Jan;107(1):169-72.
PMID: 7813270 [PubMed - indexed for MEDLINE]

122: [Lin FJ, Chen H, Chan-Yeung M.](#) Related Articles, Links

New method for an occupational dust challenge test.
Occup Environ Med. 1995 Jan;52(1):54-6.
PMID: 7697142 [PubMed - indexed for MEDLINE]

123: [Jackson L, Stahl E, Holgate ST.](#) Related Articles, Links

Terbutaline via pressurised metered dose inhaled (P-MDI) and Turbuhaler in highly reactive asthmatic patients.
Eur Respir J. 1994 Sep;7(9):1598-601.
PMID: 7995387 [PubMed - indexed for MEDLINE]

124: [Newnham DM, Lipworth BJ.](#) Related Articles, Links

Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").
Thorax. 1994 Aug;49(8):762-70.
PMID: 8091320 [PubMed - indexed for MEDLINE]

125: [Svenonius E, Arborelius M, Wiberg R, Stahl E, Svensson M.](#) Related Articles, Links

A comparison of terbutaline inhaled by Turbuhaler and by a chlorofluorocarbon (CFC) inhaler in children with exercise-induced asthma.
Allergy. 1994 Jul;49(6):408-12.
PMID: 8074262 [PubMed - indexed for MEDLINE]

126: [Hindle M, Chrystyn H.](#) Related Articles, Links

Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.
Thorax. 1994 Jun;49(6):549-53.
PMID: 8016791 [PubMed - indexed for MEDLINE]

127: [Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W.](#) Related Articles, Links

A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD.
Chest. 1994 Apr;105(4):1089-94.
PMID: 8162730 [PubMed - indexed for MEDLINE]

128: [Ismail EE, Rouse MW, De Land PN.](#) [Related Articles](#), [Links](#)
 A comparison of drop instillation and spray application of 1% cyclopentolate hydrochloride.
Optom Vis Sci. 1994 Apr;71(4):235-41.
PMID: 8047334 [PubMed - indexed for MEDLINE]

129: [Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP.](#) [Related Articles](#), [Links](#)
 Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma.
Ann Allergy. 1994 Mar;72(3):209-16.
PMID: 8129213 [PubMed - indexed for MEDLINE]

130: [Bosley CM, Parry DT, Cochrane GM.](#) [Related Articles](#), [Links](#)
 Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance?
Eur Respir J. 1994 Mar;7(3):504-9.
PMID: 8013609 [PubMed - indexed for MEDLINE]

131: [McClure RJ, Prasad VK, Brocklebank JT.](#) [Related Articles](#), [Links](#)
 Treatment of hyperkalaemia using intravenous and nebulised salbutamol.
Arch Dis Child. 1994 Feb;70(2):126-8.
PMID: 8129434 [PubMed - indexed for MEDLINE]

132: [Perring S, Summers Q, Fleming JS, Nassim MA, Holgate ST.](#) [Related Articles](#), [Links](#)
 A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler.
Br J Radiol. 1994 Jan;67(793):46-53.
PMID: 8298874 [PubMed - indexed for MEDLINE]

133: [Dor A, Krasnowska M, Malolepszy J.](#) [Related Articles](#), [Links](#)
 [Effect of vaporizing high doses of ipratropium bromide on lung ventilation in patients with chronic obstructive pulmonary disease and bronchial asthma]
Pneumonol Alergol Pol. 1994;62(1-2):75-9. Polish.
PMID: 8075617 [PubMed - indexed for MEDLINE]

134: [Wiklund L, Stierna P, Berglund R, Westrin KM, Tonnesson M.](#) [Related Articles](#), [Links](#)
 The efficacy of oxymetazoline administered with a nasal bellows container and combined with oral phenoxy-methyl-penicillin in the treatment of acute maxillary sinusitis.
Acta Otolaryngol Suppl. 1994;515:57-64.
PMID: 8067245 [PubMed - indexed for MEDLINE]

135: [Dahlback M.](#) [Related Articles](#), [Links](#)
 Behavior of nebulizing solutions and suspensions.
J Aerosol Med. 1994;7(Suppl 1):S13-8.
PMID: 10147076 [PubMed - indexed for MEDLINE]

136: [Shimizu T, Mochizuki H, Morikawa A, Kuroume T.](#) [Related Articles](#), [Links](#)
 Inhaled furosemide prevents ultrasonically nebulized water bronchoconstriction in children with both atopic and nonatopic asthma.

Chest. 1993 Dec;104(6):1723-6.
PMID: 8252951 [PubMed - indexed for MEDLINE]

137: [Mullen M, Mullen B, Carey M.](#)

[Related Articles](#), [Links](#)

 The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies.
JAMA. 1993 Oct 20;270(15):1842-5.
PMID: 8105113 [PubMed - indexed for MEDLINE]

138: [Christensen EF, Norregaard O, Jensen LW, Dahl R.](#)

[Related Articles](#), [Links](#)

 Inhaled beta 2-agonist and positive expiratory pressure in bronchial asthma. Influence on airway resistance and functional residual capacity.
Chest. 1993 Oct;104(4):1108-13.
PMID: 8404176 [PubMed - indexed for MEDLINE]

139: [Robinson NE, Derkzen FJ, Berney C, Goossens L.](#)

[Related Articles](#), [Links](#)

 The airway response of horses with recurrent airway obstruction (heaves) to aerosol administration of ipratropium bromide.
Equine Vet J. 1993 Jul;25(4):299-303.
PMID: 8354215 [PubMed - indexed for MEDLINE]

140: [McGorum BC, Dixon PM, Halliwell RE.](#)

[Related Articles](#), [Links](#)

 Responses of horses affected with chronic obstructive pulmonary disease to inhalation challenges with mould antigens.
Equine Vet J. 1993 Jul;25(4):261-7.
PMID: 8354208 [PubMed - indexed for MEDLINE]

Items 121-140 of 207

Previous

Page

7

of 11 Next

Display

Summary

Show:

20

Sort

Send to

Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



National
Library
of Medicine 

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Bo
Search PubMed for							Go	Clear	
		Limits	Preview/Index		History	Clipboard		Details	

About Entrez

Display **Abstract** Show: 20 Sort Send to Text

Text Version

1: Eur Respir J. 1994 Mar;7(3):504-9.

Related Articles, Links

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Comment in:

- [Eur Respir J. 1994 Aug;7\(8\):1554.](#)

Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance?

Bosley CM, Parry DT, Cochrane GM.

Dept of Psychiatry, United Medical School, Guy's Hospital, London, UK.

Patient compliance with an inhaled corticosteroid may be greater if it is combined with a beta-agonist. This study compared compliance with an inhaled corticosteroid (budesonide), and a short-acting inhaled beta-agonist (terbutaline sulphate), and a Turbuhaler inhaler containing a combination of the two drugs. In an open, multicentre, parallel group study 102 asthmatic patients were randomly divided into two groups, either receiving the two drugs in separate Turbuhalers or combined into one Turbuhaler. A twice daily regimen was prescribed and a preweighed metered-dose inhaler (MDI) of salbutamol was provided for rescue use. Compliance was measured using the Turbuhaler Inhalation Computer (TIC), which recorded the time and date of each inhalation over a 12 week period. Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) measurements were carried out at week 0, 6 and 12. Results from 72 patients were analysed. The average compliance was 60-70%. Treatment was taken as prescribed on 30-40% of the study days, and over-use occurred on less than 10% of days. Only 15% of patients took the drugs as prescribed for more than 80% of the days. Compliance was no greater in patients using the combined inhalers. Other ways of improving patient self-management need further investigation.

Publication Types:

- Clinical Trial
- Multicenter Study
- Randomized Controlled Trial

PMID: 8013609 [PubMed - indexed for MEDLINE]



National
Library
of Medicine 

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Bo
Search <input type="text" value="PubMed"/> for <input type="text"/>						<input type="button" value="Go"/>	<input type="button" value="Clear"/>		
		Limits	Preview/Index		History	Clipboard		Details	

About Entrez

<input type="button" value="Display"/>	<input type="button" value="Abstract"/>	Show: <input type="text" value="20"/>	<input type="button" value="Sort"/>	<input type="button" value="Send to"/>	<input type="button" value="Text"/>
--	---	---------------------------------------	-------------------------------------	--	-------------------------------------

Text Version

1: *Respir Med*. 1997 Nov;91 Suppl A:34-7.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Dose-response relationships in determining the safety:efficacy ratio.

Leff A.

Department of Medicine, University of Chicago, IL 60637, USA.

The development of inhaled agonists selective for beta 2-adrenoceptors and high potency corticosteroids has improved the treatment of asthma. The delivery of the drugs to the site of action reduces the systemic exposure and hence reduces adverse systemic events. Together, these factors have resulted in improved toxicity: therapeutic ratios. Long-acting beta 2-agonists, such as salmeterol and formoterol, and high efficacy corticosteroids, such as fluticasone propionate and budesonide, now are available for clinical use. Because suboptimal treatment of asthma causes increased morbidity and mortality, and increased costs to society, these compounds are of particular value. Risk factors associated with fatal and near-fatal asthma have been identified, and it would appear that drug treatment by metered dose inhaler per se does not cause increased asthma fatality as an independent risk factor.

PMID: 9474367 [PubMed - indexed for MEDLINE]

<input type="button" value="Display"/>	<input type="button" value="Abstract"/>	Show: <input type="text" value="20"/>	<input type="button" value="Sort"/>	<input type="button" value="Send to"/>	<input type="button" value="Text"/>
--	---	---------------------------------------	-------------------------------------	--	-------------------------------------


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Bo
Search <input type="text" value="PubMed"/> for <input type="text"/>						<input type="button" value="Go"/>	<input type="button" value="Clear"/>		
		<input type="button" value="Limits"/>	<input type="button" value="Preview/Index"/>		<input type="button" value="History"/>	<input type="button" value="Clipboard"/>		<input type="button" value="Details"/>	

About Entrez

<input type="button" value="Display"/>	<input type="button" value="Abstract"/>	Show: <input type="text" value="20"/>	<input type="button" value="Sort"/>	<input type="button" value="Send to"/>	<input type="button" value="Text"/>
--	---	---------------------------------------	-------------------------------------	--	-------------------------------------

Text Version

1: Drugs. 2000 Nov;60(5):1207-33.

Related Articles, Links

Entrez PubMed

[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)

PubMed Services
[Journals Database](#)
[MeSH Database](#)
[Single Citation Matcher](#)
[Batch Citation Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[Cubby](#)

Related Resources
[Order Documents](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)

Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.

Markham A, Jarvis B.

Adis International Limited, Auckland, New Zealand.

The long-acting beta₂-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatment of persistent asthma. Well designed studies in adults, adolescents and children aged > or =4 years, demonstrate that combined salmeterol/fluticasone propionate 50/100, 50/250 and 50/500 microg administered via a dry powder inhaler (DPI) is clinically equivalent to concurrent delivery of the same dosages of the 2 drugs via separate DPIs. In adults and adolescents, combined salmeterol/fluticasone 50/100 and 50/250 microg twice daily produced rapid improvements in lung function that were consistently greater than those in patients receiving monotherapy twice daily salmeterol 50 microg, fluticasone propionate 100 or 250 microg or placebo in 2 well designed studies. Recipients of the combination had a significantly greater probability of completing 12 weeks of treatment than patients receiving monotherapy or placebo. The combination also produced significant improvements between baseline and end-point in all secondary outcome variables (morning and evening peak expiratory flow, daytime symptom scores, days and nights without asthma symptoms and requirements for as-needed beta-agonists) and health-related quality of life (QOL). Combination therapy was superior to monotherapy with salmeterol and placebo for all outcomes in both studies, and was superior to fluticasone propionate 100 microg for all but 1 outcome (nights without awakenings) in 1 study. Similar results were obtained in patients who had previously been using short acting beta₂-agonists alone. Combined twice daily salmeterol/fluticasone propionate 50/100 and 50/250 microg produced greater improvements in lung function than inhaled budesonide at higher dosages than fluticasone propionate in the combination. Combined salmeterol/fluticasone propionate 50/250 microg produced similar improvements in lung function to concurrent budesonide 800 microg plus formoterol 12 microg when given twice daily for 12 weeks. In another 12-week trial, combined salmeterol/fluticasone propionate 50/100 microg was more effective than oral montelukast 10 mg/day plus fluticasone propionate

100 microg twice daily in patients with suboptimally controlled asthma. Salmeterol/fluticasone is more cost effective than monotherapy with fluticasone propionate or budesonide. The most frequent adverse events associated with salmeterol/fluticasone propionate are headache, throat irritation, hoarseness and candidiasis. CONCLUSION: Combined salmeterol/fluticasone propionate is as effective as the 2 drugs given concurrently via separate inhalers and significantly more effective than either drug given alone at the same nominal dosage. The combination is also significantly more effective than montelukast plus fluticasone propionate or monotherapy with inhaled budesonide. Furthermore, the combination is more cost effective than inhaled corticosteroid monotherapy.

Publication Types:

- Review
- Review, Tutorial

PMID: 11129128 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01